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Abstract
Background: The aim of this study is to compare the effectiveness of
131I therapy between three groups of DTC
patients who received 30, 60 or 100 mCi for thyroid remnant ablation after total thyroidectomy and were
postoperatively judged with low risk of cancer recurrence.
Methods: The project was designed as a two-stage, prospective randomized clinical trial. In 1998-2001 in a
randomized prospective study the early comparison of treatment with 30 mCi vs 60 mCi suggested the lower
131I activity to be less effective, whereas in 2003-2005 the comparison between 60 vs 100 mCi showed no significant
differences. The present study comprises the long-term assessment of the disease course in 3 study groups.
Results: A group of 309 DTC patients (285 women and 24 men) with no clinical, histopathological, sonographical
or biochemical signs of persistent disease were included after total thyroidectomy and appropriate extent of neck
lymph node dissection (265 with papillary and 44 with follicular thyroid cancer). For radioiodine thyroid remnant
ablation, 30 mCi of
131I was applied in 86 patients, whereas 60 mCi in 128 and 100 mCi in 95 patients. The median
follow-up was 10 years (2-12) for subjects treated with 30 mCi and 60 mCi and 6 years (2-6) for patients treated
with 100 mCi of
131I. In the first evaluation, published previously, we observed that because of incomplete thyroid
remnant ablation, the second
131I treatment was necessary in 10% patients, without difference between groups
treated with 60 and 100 mCi and in 22% patients treated with 30 mCi. All patients entered full remission. To
evaluate the long-term outcome of the adjuvant
131I treatment, the course of the follow-up and the most recent
disease status were assessed by sonography, radiological examinations and serum Tg estimation (on LT4-
suppressive treatment). Within the whole observation period local relapse was stated in 2 (2.4%), 4 (3%) and 3 (3%)
patients treated with
131I activities of 30 mCi, 60 mCi and 100 mCi respectively and serum Tg concentration on
LT4-suppressive treatment was low, without differences between groups.
Conclusions: No significant differences in the 5 years efficacy of thyroid remnant radioiodine ablation using 30, 60
and 100 mCi were observed in low-risk DTC patients operated by total thyroidectomy and neck lymph node
dissection. However, patients treated initially with 30 mCi, required second course of radioiodine in 22%, while this
was necessary only in 13,3% and 11,2% of patients treated with 60 mCi and 100 mCi respectively.
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Postoperative complementary radioiodine (
131I) therapy is
the standard treatment for differentiated thyroid cancers
(DTC). One aim of this therapy is to destroy thyroid rem-
nant to remove their competition with cancer cells for
secretion of thyroglobulin or
131I uptake. Thus, the name
of thyroid remnant ablation is used. The second aim is to
treat putative cancer micrometastases. Only the adjuvant
131I therapy enables the detection of functional microme-
tastases, which are visible during the post-therapeutic total
body scan, but not on X-ray or CT images [1]. Therefore
it is important to ensure, both for the healthy follicular
cells and thyroid cancer cells to absorb appropriately high
radiation doses. The absorbed dose depend, among others,
on the ability of the cells to trap and cumulate
131I. The
capability of thyroid cancer cells is much lower than of the
healthy ones so the
131I activity sufficient for thyroid rem-
nant ablation might not be sufficient to treat cancer
micrometastases. That is why the evaluation of the effec-
tiveness of the adjuvant
131I therapy must include the
assessment of thyroid remnant ablation effectiveness as
well as of micrometastases treatment. The latter can be
done only by the long-term disease follow-up.
Usually, most DTC recurrences are diagnosed within
first 5 years postoperatively. Adjuvant
131I treatment
increases specificity of the further serum thyroglobulin
follow-up, as in patients operated because of differen-
tiated thyroid carcinoma but not treated by
131It h e
source of Tg might be both healthy thyroid cells and
cancer cells. After successful thyroid remnant ablation
thyroglobulin may be secreted by only cancer cells. Also
the adjuvant therapy improves the sensitivity and speci-
ficity of the further DTC
131I-based diagnostic by abol-
ishing the competition amongst healthy follicular cells
and cancer cells to uptake the
131I.
For patients with differentiated thyroid cancer various
therapeutic activities are used to carry out the adjuvant
131I treatment: from 30 to 200 mCi (1,1 - 7,4 GBq) [2-7].
The most favorable activity has not been established yet
although a great deal of research has been performed.
Early papers evaluating the efficiency of the adjuvant
131I
treatment mainly focused on its thyroid ablation role and
were rather observational. They did not prove any relation
between therapeutic activity and ablation effectiveness. In
1996, Bal et al. carried out a prospective randomized clini-
cal trial in which they evaluated the effectiveness of some
activities. Then divided the patients into four groups
which were administered respectively: 25-34 mCi, 35-64
mCi, 65-119 mCi and finally 120-200 mCi. They con-
cluded that 50 mCi was the most effective activity and that
an increase in activity did not bring about any therapeutic
benefits. Mazaferri compared retrospectively the outcome
in 1,004 patients with differentiated thyroid carcinoma,
whose median follow-up time was on average 15 years,
however, did not indicate the optimal dose of
131I neces-
sary to achieve the best therapeutic effect. The prospective
randomized study published in 2008 by Mäenpää et al.
evaluated the effectiveness of the thyroid remnant ablation
and long-term results of adjuvant
131I therapy and did not
prove the treatment with 100 mCi being better than 30
mCi [6]. Thus, we decided to perform own prospective
study. The aim of this study is to compare the effective-
ness of adjuvant
131I therapy between three groups of
DTC patients who were treated by total thyroidectomy
and lymph neck dissection and evaluated postoperatively
to be free from disease. They received respectively 30, 60
and 100 mCi of radioiodine for thyroid remnant ablation.
Patients and methods
The project was designed as a two-stage, prospective
randomized clinical trial.
The first part of the study was an early evaluation of the
effectiveness of thyroid remnant
131I ablation treatment
and was described in our previous papers [8-10]. In 1998-
2001 210 low risk DTC patients, diagnosed with differen-
tiated thyroid carcinoma, were randomly allocated to
receive either 1100 MBq (30 mCi), or 2200 MBq (60 mCi)
activity of
131I following total thyroidectomy and in most
cases, central lymph node dissection [8,9]. Only patients
without lymph node metastases, staged pT1b-T3 or Tx and
N0 or Nx were included. The condition to show stimulated
Tg level <30 ng/ml was fulfilled for all of them.
From 2003 to 2005 as the completion of the range of
131I activities analyzed, we compared the effectiveness of
two
131I activities, 60 mCi and 100 mCi. For this goal,
224 patients staged pT1b-T4 N0-1 were included, if they
were diagnosed disease-free following total thyroidect-
omy and central/lateral lymph node dissection, when
necessary.
131I treatment was performed after thyroid hormone
withdrawal. A successful thyroid remnant ablation was
defined as the absence of thyroid bed uptake in
131I neck
scan and the stimulated thyroglobulin (Tg) value <
10 ng/ml, as judged after 12 months post
131I therapy [10].
The second stage of the study, presented now, com-
prised the long-term assessment of the disease follow-
up in the study groups. 309 DTC patients (285 women
and 24 men) with no clinical signs of persistent disease
were included. There were 267 subjects with papillary
and 44 with follicular carcinoma. 86 patients were
initially treated with 30 mCi (group A), 128 with 60
m C i( g r o u pB )a n d9 5w i t h1 0 0m C i( g r o u pC )p o s t
thyroidectomy.
In group A there were only patients in pT1b-T3 N0 M0
stage, in other cohorts the wider range of patients in
pT1b-T4,N 0-N1 M0 were included. The distribution of
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the majority, in all groups was similar (table 1).
The median follow-up was 10 years (range 2-11 years)
for subjects treated with 30 mCi and 60 mCi and
6 years (range 2-6 years) for patients treated with
100 mCi of
131I. Only 5 patients in group A and 12 in
group B and C were observed less than 6 years.
The most recent evaluation of the disease status and
outcome were assessed by sonography, radiological
examinations and serum Tg level (on LT4-suppressive
treatment).
Results
In the early evaluation, described in details elsewhere
[8,9], there were 22% cases of incomplete thyroid rem-
nant ablation after 30 mCi of
131I, requiring the second
131I therapy and 13,3% and 11,2% after 60 and 100 mCi
respectively. The freedom from disease was confirmed
by the low stimulated Tg in all patients during the eva-
luation done 6-12 months after the completion of adju-
vant
131I therapy.
During the whole follow-up, the local relapse was sta-
ted in 2 (2.4%), 4 (3%) and 3 (3%) patients treated with
131I activities of 30 mCi, 60 mCi and 100 mCi respec-
tively, without differences between groups.
If only patients in early stage of the disease were
included (291 pT1-3,N0-x), local relapse was observed in
2 patients in group A and 3 and 2 in groups B and C
respectively. Locoregional relapses were diagnosed after 8
and 3 years after surgery in group A, after 2, 4 and 9
years after surgery in group B and 1, 2, 3 years after sur-
gery in group C, without any differences between groups.
During the whole follow-up we did not observe any
distant recurrence in any of the patient.
The median last serum Tg level on LT4-suppressive
treatment was low in all groups. Serum Tg concentra-
tion above the threshold of the method’s sensitivity was
observed in only one third of patients. Just a few sub-
jects presented an increase serum level Tg without any
localization of the cancer focus (table 2).
Tg serum level evaluated on LT4-suppressive treat-
ment analyzed in the group of patients with pT1-3,N0-x
resembled data on lack of differences in Tg serum level
in the whole group.
For some patients we performed a full diagnostic pro-
cedure during endogenous TSH stimulation, especially
for those with slightly increased suppressed Tg level.
For all of them stimulated Tg serum level was low and
there were no significant differences between the
groups. There were no localized disease cases either by
131I scan or by radiological examinations.
Discussion
Postoperative
131I therapy is the standard treatment for
differentiated thyroid cancers.
In the USA it is only used with patients in more
advanced DTC stage [2,11]. In such cases the effective-
ness of this method is undisputed. It has been proved
that it decreases the risk of the recurrence and death due
to DTC [11,12]. It is more commonly used in Europe
although it is still questionable if it is necessary with the
patients in early disease stage [13]. However, it is impor-
tant to remember that it allows a better follow-up
through the improvement of specificity of serum thyro-
globulin measurement and sensitivity of the whole body
scan. Thus, it is routinely used in many European coun-
tries and recommended by Polish guidelines in all DTC
cases but papillary microcancer [14]. In our clinical prac-
tice we use routinely 100 mCi
131I for thyroid remnant
ablation. However, being aware of the possibility to use
lesser activities, we decided to perform a prospective ran-
domized trial with long term outcome. We plan to
extend our observation till 10 years follow up will be
reached, however, an interim analysis has been planed
after 5 years and this short communication present its
result. In the previous, initial part of the study we found
that the 30 mCi activity was less effective than 60 mCi as
more patients needed second
131I treatment [9], but
60 mCi was as good as 100 mCi [10]. The later evaluation
Table 1 TNM classification of DTC patients
T1b T2 T3 T4 Tx N0 N1 Nx Total
Group A (30 mCi) 13 (15%) 42 (48%) 9 (10%) 0 20 (25%) 86 (100%) 46 (53%) 0 40 (47%) 86 (100%)
Group B (60 mCi) 37 (29%) 59 (46%) 11 (8%) 7 (5%) 14 (10%) 128 (100%) 74 (57%) 5 (4%) 49 (39%) 128 (100%)
Group C (100 mCi) 22 (23%) 50 (52%) 5 (4%) 7 (7%) 13 12(%) 95 (100%) 53 (55%) 13 (14%) 29 (31%) 95 (100%)
Total 72 151 25 14 47 309 173 18 118 309
Table 2 Serum Tg level on LT4-suppressive treatment, as
judged during the most recent examination in all
patients.
Serum Tg level GROUP A GROUP B GROUP C
No 86 128 95
Median 0,1 ng/ml 0,17 ng/ml 0,17 ng/ml
Higher than 0,17 ng/ml 21% 28% 29%
Maximal 1,1 ng/ml 6,4 ng/ml 8,15 ng/ml
Number of patients showing
Tg>1 ng/ml
14 *4 *
*In none of the patients the extended evaluation, including
131I scan, revealed
disease foci.
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show significant differences in the effectiveness of 30, 60
and 100 mCi activities. In our study the majority of
patients were diagnosed with early stage of the disease,
so the results are related to low risk DTC patients treated
by radical surgery. However, one limitation is obvious: in
the group treated initially by 30 mCi of
131I 22% of
patients required second course of
131I for complete thyr-
oid ablation. Thus, in fact, the cumulative
131I activity
administered was larger in 22% of patients and exceeded
100 mCi. The same occurred in 13,3% and 11,2% of
patients treated with 60 and 100 mCi respectively. This
will be considered at the final evaluation, however,
already now we have to bear in mind that the apparent
equality of various activities of
131I has to be interpreted
with caution. All for whom the initial treatment proved
insufficient during the first assessment were treated again
with a higher activity which might have influenced the
good general outcome of radioiodine treatment in the
group treated with lower activities.
Conclusions
In the analyzed groups of patients no significant differences
in 5 years efficacy of
131I thyroid remnant ablation were
observed. However, to reach this goal, 22% of patients trea-
ted with 30 mCi required second course of radioiodine,
while this was necessary only in 13,3% and 11,2% of
patients treated with 60 and 100 mCi respectively.
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